ad image

Jazz Pharmaceuticals

1 / 1
Jazz Pharmaceuticals
Acquisition

Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc

Jazz Pharmaceuticals

PR-M05-21-005-999May 06, 2021
Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness
Study Results

Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of JZP-258 in Adult Narcolepsy Patients with Cataplexy and Excessive Daytime Sleepiness

Nice Insight

PR-M03-19-NI-085Mar 29, 2019
Jazz Pharmaceuticals
FDA Approval

Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Jazz Pharmaceuticals

PR-M11-18-NI-006Nov 02, 2018
Jazz Pharmaceuticals
FDA Approval

Jazz Pharmaceuticals Announces FDA Approval of Xyrem® (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

Jazz Pharmaceuticals

PR-M10-18-NI-100Oct 30, 2018
1 / 1